Detailed Narrative
Q1 FY26 Performance Overview
PI Industries reported Q1 FY26 revenue of ₹19,005 million, marking an 8% year-on-year decline but a 7% sequential growth. This performance was broadly in line with the company's H2-weighted⚖️ FY26 plan, which anticipated transitional softness in AgChem exports due to customer inventory balancing. Despite the revenue dip, gross margins expanded to 57.4%, a 5.7 percentage point increase, and EBITDA margins remained resilient at 27.5%, driven by product mix and cost optimization.
Pharma and Biologicals Segment Growth
The pharma business demonstrated strong momentum, achieving a 186% year-on-year revenue growth, supported by deepening relationships with biotech and big pharma innovators. The global biological business, acquired in August 2024 (Plant Health Care), contributed $3-4 million in the quarter. Management aims to grow the pharma revenue 2 to 3 times in the next 3-4 years and onboard 3-4 large pharma clients, with two already secured and two more expected by year-end.
Domestic Business and Regulatory Headwinds
The domestic business grew 6% year-on-year, benefiting from favorable monsoons and a strong product portfolio. However, this growth was hampered by temporary regulatory challenges🌐 in the biologicals segment, which contributes approximately 20% of domestic revenue. Management expects these regulatory issues to be resolved within a month or so, with positive court proceedings, as it is a top priority for the Government of India.
Strategic Initiatives and Product Pipeline
The company is actively pursuing diversification into electronic and specialty chemicals, having commercialized 5-7 products in this area with a strong growth outlook for the next 4-5 years. In the AgChem space, PI Industries plans to commercialize 6-7 new molecules in the remaining quarters of FY26 and has a development pipeline of over 20 new products. The registration for India's first discovery molecule, PIOXANILIPROLE, has been filed, with commercialization anticipated in about two and a half years.
Capital Allocation and Financial Health
PI Industries plans a capital expenditure of ₹700-800 crore for FY26, focusing on future growth engines including pharma and biologicals. The company maintains a strong balance sheet with a net worth of ₹1,06,003 million and a healthy net cash balance of ₹41,554 million, providing flexibility for its CAPEX plans. The effective tax rate is guided to be 22-23% for the next 2-3 years.
Working Capital and Outlook
Trade working capital days increased to 91 days from 73 days in March 2025, primarily due to market inventories and collection slowness in agrochemicals, rather than sales quality issues. Despite Q1 softness, management remains 'conservatively positive' on achieving single-digit revenue growth for FY26, anticipating an acceleration in supplies and demand in H2, supported by CSM schedules and expected resolution of biological regulatory issues.